Parcourir par sujet "Glioblastoma"

Automated differentiation of glioblastomas from intracranial metastases using 3T MR spectroscopic and perfusion data

Tsolaki, E.; Svolos, P.; Kousi, E.; Kapsalaki, E.; Fountas, K.; Theodorou, K.; Tsougos, I. (2013)

Purpose Differentiation of glioblastomas from metastases is clinical important, but may be difficult even for expert observers. To investigate the contribution of machine learning algorithms in the differentiation of ...

Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells

Vlachostergios, P. J.; Hatzidaki, E.; Stathakis, N. E.; Koukoulis, G. K.; Papandreou, C. N. (2013)

The efficacy of treatment for glioblastoma multiforme is currently limited by the development of resistance, particularly, but not exclusively, due to the expression of the DNA repair enzyme O6-methylguanine methyltransferase ...

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner

Vlachostergios, P. J.; Hatzidaki, E.; Befani, C. D.; Liakos, P.; Papandreou, C. N. (2013)

Development of drug resistance after standard chemotherapy for glioblastoma multiforme (GBM) with temozolomide (TMZ) is associated with poor prognosis of GBM patients and is at least partially mediated by a direct DNA ...

Dual IRE1 RNase functions dictate glioblastoma development

Lhomond S., Avril T., Dejeans N., Voutetakis K., Doultsinos D., McMahon M., Pineau R., Obacz J., Papadodima O., Jouan F., Bourien H., Logotheti M., Jégou G., Pallares-Lupon N., Schmit K., Le Reste P.-J., Etcheverry A., Mosser J., Barroso K., Vauléon E., Maurel M., Samali A., Patterson J.B., Pluquet O., Hetz C., Quillien V., Chatziioannou A., Chevet E. (2018)

Proteostasis imbalance is emerging as a major hallmark of cancer, driving tumor aggressiveness. Evidence suggests that the endoplasmic reticulum (ER), a major site for protein folding and quality control, plays a critical ...

The expression of the epitope H recognized by the monoclonal antibody H is higher in astrocytomas compared to anaplastic astrocytomas and glioblastomas

Arvanitis, D. L.; Arvanitis, L. D.; Panourias, I. G.; Kitsoulis, P.; Kanavaros, P. (2005)

The epitope H contains an O-linked N-acetylglucosamine residue in a specific conformation and/or environment recognized by the monoclonal antibody H (mAbH). mAbH stains two bands with Mr x10-3 of 209 and 62 in lysates of ...

Focus on the use of resveratrol as an adjuvant in glioblastoma therapy

Dionigi L., Ragonese F., Monarca L., Covino S., de Luca A., Iannitti R.G., Bastioli F., Moulas A.N., Allegretti M., Fioretti B. (2020)

Glioblastoma (GB) represents the most common and malignant form of glioma cancer. The Gold Standard in Glioblastoma is neurosurgical tumor removal and radiotherapy treatment in concomitant with temo-zolomide (TMZ). ...

Glioblastoma Multiforme in a Patient with Celiac Disease: Management of Seizures After Gross Total Tumor Resection

Fotakopoulos G., Brotis A.G., Kotlia P., Fountas K. (2018)

Background: A 55-year-old woman with a history of celiac disease presented with focal seizures and a mass lesion located at the left frontal lobe. Management of seizures in these patients is challenging. Case Description: ...

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours

Koukourakis, M. I.; Koukouraki, S.; Fezoulidis, I.; Kelekis, N.; Kyrias, G.; Archimandritis, S.; Karkavitsas, N. (2000)

The blood-brain barrier is a major obstacle for the chemotherapeutic drugs to effectively reach primary or secondary brain tumours, Stealth® liposomal drugs are highly accumulated in tumoural tissues. In the present study ...

Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo

Le Reste P.J., Pineau R., Voutetakis K., Samal J., Jégou G., Lhomond S., Gorman A.M., Samali A., Patterson J.B., Zeng Q., Pandit A., Aubry M., Soriano N., Etcheverry A., Chatziioannou A., Mosser J., Avril T., Chevet E. (2020)

Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for ...

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NF kappa B and mutant p53

Vlachostergios, P. J.; Hatzidaki, E.; Papandreou, C. N. (2013)

The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma resistance to alkylating agents. Several strategies have been used to induce sensitization to alkylator-based treatments, ...

Simulation of magnetic nanoparticles crossing through a simplified blood-brain barrier model for Glioblastoma multiforme treatment

Gkountas A.A., Polychronopoulos N.D., Sofiadis G.N., Karvelas E.G., Spyrou L.A., Sarris I.E. (2021)

Background and Objectives: Glioblastoma multiforme is considered as one of the most aggressive types of cancer, while various treatment techniques have been proposed. Magnetic nanoparticles (MNPs) loaded with drug and ...

Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis

Magouliotis D.E., Asprodini E.K., Svokos K.A., Tasiopoulou V.S., Svokos A.A., Toms S.A. (2018)

Background: We aim to review the available literature on patients suffering from glioblastoma treated with tumor-treating fields (TTFields) plus radio chemotherapy or conventional radio chemotherapy alone, to compare the ...